

development through collaborative research opportunities with the inventors.

Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes

Michael Schmidt *et al.* (NIDCR)
U.S. Provisional Application No. 60/
676,604 filed 29 April 2005 (HHS
Reference No. E-179-2005/0-US-01)
Licensing Contact: Jesse S. Kindra; (301)
435-5559; kindraj@mail.nih.gov.

This invention relates to new adeno-associated viruses (AAV), vectors and particles derived therefrom and also provides methods for delivering specific nucleic acids to cells using the AAV vectors and particles. Vectors based on these new AAV serotypes may have a different host range and different immunological properties, thus allowing for more efficient transduction in certain cell types. In addition, characterization of these new serotypes will aid in identifying viral elements required for tissue tropism.

More specifically, in order to identify and characterize novel AAV isolates for development as gene therapy vectors, the inventors screened approximately one hundred (100) viral stocks. The inventors cloned and sequenced the genomes of AAVs found in twelve (12) simian adenovirus isolates and determined that the AAVs were novel. Ten (10) of these isolates had high similarity to AAV1 and AAV6 (>98%). Despite the high homology to AAV6, these novel AAVs demonstrated distinct cell tropisms and reactivity towards a panel of lectins, suggesting that they may use a distinct entry pathway. Therefore, these novel AAVs may be useful for gene therapy applications.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

Anti-Mesothelin Antibodies Useful for Immunological Assays

Ira H. Pastan and Masanori Onda (NCI)
U.S. Provisional Application No. 60/
681,104 filed 12 May 2005 (HHS
Reference No. E-015-2005/0-US-01),
Licensing Contact: Jesse S. Kindra; (301)
435-5559; kindraj@mail.nih.gov.

This invention provides antibodies that have a surprisingly good combination of affinity for mesothelin and ability to be used in immunological assays for detecting the presence of mesothelin in biological samples. The invention further relates to methods of using antibodies and kits comprising them. The antibodies can also be used to target toxins and other agents to cells

expressing mesothelin, and can be used in methods and medicaments for inhibiting the growth of such cells.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cells

Gergely Szakacs *et al.* (NCI)
HHS Reference No. E-075-2004/2-
PCT-01 filed 17 Jun 2005
Licensing Contact: Jesse S. Kindra; (301)
435-5559; kindraj@mail.nih.gov.

There is an important need to overcome cancer multiple drug resistance (MDR). ATP-binding cassette (ABC) transporters are a family of transporter proteins that contribute to drug resistance via ATP-dependent drug efflux pumps. Accordingly, based on the expression profile of 48 ABC transporters in sixty (60) cell lines, the present invention provides a method to identify (1) drugs that retain action in cells expressing MDR proteins, (2) compounds that reduce MDR by interfering with the efflux pumps. In addition, the invention describes a method to identify compounds whose antiproliferative effect is potentiated by the ABCB1/MDR1 transporter. These compounds might avoid the well-documented side-effects observed in clinical trials of "classical" MDR1 inhibitors and may serve as leads for development of novel anti-cancer agents to treat resistant disease.

Dated: July 15, 2005.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 05-14499 Filed 7-21-05; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign

language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council for Human Genome Research.

Date: September 11-13, 2005.

Closed: September 11, 2005, 7 p.m. and 10 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Open: September 12, 2005, 8:30 a.m. to 12 p.m.

Agenda: To discuss matters of program relevance.

Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892.

Closed: September 12, 2005, 1 p.m. to 5 p.m. on September 13, 2005.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892.

Contact Person: Mark S. Guyer, PhD, Director of Extramural Research, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9305, Bethesda, MD 20892, 301-496-7531, guyerm@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://www.genome.gov/11509849>, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: July 15, 2005.

Anthony M. Coelho, Jr.,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 05-14492 Filed 7-21-05; 8:45 am]

BILLING CODE 4140-01-M